麻酔関連薬物の安定供給に向けて

Toward a Stable Supply of Perioperative Medicines

はじめに

　日本製薬団体連合会の安定確保委員会が実施した「医薬品供給状況にかかる調査（2025年3月）」によると，薬価削除予定品目を除く全品目のうち，限定出荷と供給停止を合わせた品目割合は13.3％となり^1），日常診療に必要な医薬品が届かない状況が長期化している。企業において安定供給に支障を来す要因はさまざまに存在するが，本論文においては，丸石製薬株式会社（以下，当社）が経験した要因ごとの供給不安の具体例とその対応策，また今後の課題を紹介したい。

　According to the Survey on the Status of Pharmaceutical Supply（March 2025）conducted by the Stable Drug Supply Committee of the Federation of Pharmaceutical Manufacturers’ Associations of Japan, 13.3％ of all products listed in the National Health Insurance（NHI）drug price list―excluding those scheduled for delisting―were subject to either a limited supply or a suspended supply. This situation indicates a prolonged shortage of essential medicines for routine clinical practice. The factors hindering the achievement of stable supplies of essential medicines vary across pharmaceutical companies. This article presents specific examples of supply disruptions encountered by Maruishi Pharmaceutical Company, categorized by the disruptions’ cause（s）：（ⅰ）the COVID-19 pandemic, （ⅱ）difficulties in procuring raw materials, and（ⅲ）issues related to corporate management systems. The countermeasures implemented are outlined, and the remaining challenges moving forward are discussed.